PART I Overview We are a clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. With the evolving understanding 6 Table of Contents of the pathogenesis of autoimmune diseases, along with the expansion of promising immunology-based pharmacologic targets, we are building an I&I focused biopharmaceutical company. Our core business strategy combines disciplined product can...
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001104659-26-027964 | EDGAR | 131K words |
| 2025-03-11 | 2024-12-31 | 0001558370-25-002631 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001104659-25-109753 | EDGAR | 73K words |
| 2025-08-12 | 2025-06-30 | 0001558370-25-011147 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001558370-25-007803 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001558370-24-015162 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001104659-26-037821 | EDGAR | 42K words |
| 2026-03-16 | 0001104659-26-027961 | EDGAR | — |
| 2026-02-13 | 0001104659-26-015314 | EDGAR | — |
| 2026-01-05 | 0001104659-26-000402 | EDGAR | — |
| 2025-12-15 | 0001104659-25-121182 | EDGAR | — |
| 2025-11-12 | 0001104659-25-109737 | EDGAR | — |
| 2025-10-27 | 0001104659-25-102317 | EDGAR | — |
| 2025-10-08 | 0001104659-25-097663 | EDGAR | — |
| 2025-09-02 | 0001104659-25-085982 | EDGAR | — |
| 2025-08-12 | 0001104659-25-076464 | EDGAR | — |
31 total filings indexed. 15 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001953926 |
| Ticker | ZBIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.zenasbio.com |
| Listed | 2024-09-13 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report